tirzepatide for minor weight loss Medical in Sacramento CA The promise of tirzepatide: A

Aging (Albany NY) 13, 63756405

Social pressure can also help drive motivation

Phase 3 trial data from 604 adults in China showed weight loss of up to 19.3 percent at 48 weeks Comparable trials of Zepbound reported up to 20.9 percent weight loss at 72 weeks Hansoh reported lower rates of nausea and vomiting, suggesting potential tolerability advantages Regeneron is now planning a global phase 3 registrational program and is exploring combination therapy with its PCSK9 inhibitor Praluent

Clinicians should be aware that the gastrointestinal effects of Wegovy, particularly nausea and delayed gastric emptying, could theoretically affect the absorption of levothyroxine if both medications are taken simultaneously

Semaglutide imitates the action of the GLP-1 hormone, which plays a key role in controlling appetite and managing glucose levels